23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Krystal Biotech, Inc. › 2025-2026

Krystal Biotech, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 373Asset managers, any item
  • 2,267Fund votes
  • May 15, 2026Meeting date

Results at a glance

Meeting of May 15, 2026: 5 items on Krystal Biotech, Inc.’s Form 8-K, filed May 20, 2026: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (16.0%, 11.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Krystal Biotech, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Krystal Biotech, Inc.

These tallies are Krystal Biotech, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 20, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Krystal Biotech, Inc. — official shareholder meeting results, meeting held May 15, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Krish S. Krishnan 23,802,920---- 3,079,1941,581,473 89%Passed (calculated)—
Elect Director: Christopher Mason 22,581,854---- 4,300,2601,581,473 84%Passed (calculated)—
2. Ratification of Appointment of Independent Registered Public Accounting Firm 28,443,15515,4344,998 ---- 99.9%Approved—
3. Non-Binding, Advisory Vote on Named Executive Officer Compensation 25,679,3181,195,7887,008 --1,581,473 96%Approved—
4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the Company's board of directors and the defendants in the litigation entitled Corbin v 21,374,0212,349,5503,158,543 --1,581,473 90%Passed (calculated)—

Source: Krystal Biotech, Inc., Form 8-K, filed with the SEC on May 20, 2026 — read the filing on EDGAR.

How asset managers voted at the Krystal Biotech, Inc. 2025-2026 meeting

373 asset managers disclosed a vote on at least one Krystal Biotech, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Christopher Mason

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 22,581,854WITHHELD: 4,300,260
Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Class III Directors: Christopher Mason

Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Christopher Mason”): 22,581,854 for, 4,300,260 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 11,055,090 for, 1,588,277 withheld, 117,825 abstained, 18,548 not voted.

FOR
FOR: 11,055,090ABSTAIN: 117,825WITHHOLD: 1,588,277NOT VOTED: 18,548
Largest asset managers voting on “Election of Class III Directors: Christopher Mason” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity3,581,0660 00For
Vanguard2,684,3670 150For
BlackRock2,160,3670 00For
Capital Group755,1810 00For
State Street1,6840 0694,945Withhold
T. Rowe Price373,8460 00For
Manager Directed Portfolios349,2910 00For
First Trust00 0349,271Withhold
Charles Schwab211,3390 00For
Invesco188,6980 00For
Franklin Custodian Funds150,0000 00For
TIAA93,1040 00For
WILLIAM BLAIR FUNDS00 091,520Withhold
Voya67,3170 00For
Equitable43,2740 020,060Mixed
NEW ECONOMY FUND62,8450 00For
Jackson National00 58,4320Abstain
Dimensional00 051,803Withhold
Janus Detroit Street Trust00 048,180Withhold
Columbia Threadneedle44,1210 00For
Nuveen43,7710 00For
John Hancock6,1600 29,4810Mixed
Victory Capital00 034,820Withhold
Lincoln Financial1,2610 027,691Withhold
Pacific Life26,8510 00For

Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).

Elect Director: Krish S. Krishnan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 7 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 23,802,920WITHHELD: 3,079,194
Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: Election of Class III Directors: Krish S. Krishnan

Krystal Biotech, Inc.’s own tally for this item (“Elect Director: Krish S. Krishnan”): 23,802,920 for, 3,079,194 withheld, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 106 asset managers below reported 11,716,487 for, 926,885 withheld, 117,820 abstained, 18,548 not voted.

FOR
FOR: 11,716,487ABSTAIN: 117,820WITHHOLD: 926,885NOT VOTED: 18,548
Largest asset managers voting on “Election of Class III Directors: Krish S. Krishnan” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity3,581,0660 00For
Vanguard2,680,6560 103,715For
BlackRock2,160,3670 00For
Capital Group755,1810 00For
State Street695,7160 0913For
T. Rowe Price373,8460 00For
Manager Directed Portfolios349,2910 00For
First Trust00 0349,271Withhold
Charles Schwab211,3390 00For
Invesco188,6980 00For
Franklin Custodian Funds150,0000 00For
TIAA93,1040 00For
WILLIAM BLAIR FUNDS00 091,520Withhold
Voya00 067,317Withhold
Equitable43,2740 020,060Mixed
NEW ECONOMY FUND62,8450 00For
Jackson National00 58,4320Abstain
Dimensional00 051,803Withhold
Janus Detroit Street Trust00 048,180Withhold
Columbia Threadneedle44,1210 00For
Nuveen43,7710 00For
John Hancock6,1600 29,4810Mixed
Victory Capital00 034,820Withhold
Lincoln Financial18,0070 010,945Mixed
Pacific Life26,8510 00For

Showing the 25 largest of 106 asset managers. All 106 are in the interactive database (link above).

Non-Binding, Advisory Vote on Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 11 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 25,679,318AGAINST: 1,195,788

Prior year: 94.1% for (May 16, 2025 meeting) ▲ 1.5 pts

Details: description as filed, official tally, votes by 372 asset managers

Description as filed by funds: Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.

Krystal Biotech, Inc.’s own tally for this item (“3. Non-Binding, Advisory Vote on Named Executive Officer Compensation”): 25,679,318 for, 1,195,788 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three: Non-Binding, Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers for the fiscal year ended December 31, 2025, as disclosed in the Company's proxy sta…”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 106 asset managers voting on “Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity3,581,0660 00For
Vanguard2,684,3793 00For
BlackRock2,160,3670 00For
Capital Group0755,181 00Against
State Street696,266363 00For
T. Rowe Price373,8460 00For
Manager Directed Portfolios349,2910 00For
First Trust349,2710 00For
Charles Schwab211,3390 00For
Invesco188,6980 00For
Franklin Custodian Funds150,0000 00For
TIAA93,1040 00For
WILLIAM BLAIR FUNDS91,5200 00For
Voya67,3170 00For
Equitable63,3340 00For
NEW ECONOMY FUND062,845 00Against
Jackson National58,4320 00For
Dimensional51,8030 00For
Janus Detroit Street Trust48,1800 00For
Columbia Threadneedle44,1210 00For
Nuveen43,7710 00For
John Hancock35,6410 00For
Victory Capital34,8200 00For
Lincoln Financial28,9520 00For
Pacific Life26,8510 00For

Fund voting reports, all 106 managers: 11,923,880 for, 831,534 against, 4,676 abstained, 18,548 not voted, 54 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 291 asset managers voting on “Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,310,7290 00For
Avoro Capital Advisors LLC2,542,2980 00For
State Street1,150,4935,274 00For
BlackRock849,05011,386 00For
Capital Group0823,759 00Against
Redmile Group, LLC673,5050 00For
GEODE CAPITAL MANAGEMENT, LLC617,8710 00For
Hood River Capital Management LLC565,1700 00For
T. Rowe Price510,3570 00For
Frazier Life Sciences Management, L.P.481,3070 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC319,1600 00For
Charles Schwab241,2020 00For
Vanguard216,8940 00For
Invesco201,68613 00For
Soleus Capital Management, L.P.201,0010 00For
FRANKLIN ADVISERS INC175,3580 00For
Northern Trust164,4952,506 00For
PRINCIPAL GLOBAL INVESTORS161,1160 00For
Woodline Partners LP150,6160 00For
Nuveen141,5900 00For
Janus Henderson112,9300 00For
PICTET ASSET MANAGEMENT SA108,7370 00For
MELLON INVESTMENTS Corp101,8500 00For
Voya97,5450 00For
S SQUARED TECHNOLOGY, LLC86,2150 00For

Institutional-manager reports, all 291 managers: 15,683,475 for, 1,101,445 against, 17 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 21,374,021AGAINST: 2,349,550
Details: description as filed, official tally, votes by 126 asset managers

Description as filed by funds: Approval of the Company's Non- Employee Director Compensation Policy.

Krystal Biotech, Inc.’s own tally for this item (“4. Non-Employee Director Compensation Policy The Company's unaffiliated stockholders (i.e., excluding the members of the the Company's board of directors and the defendants in the litigation entitled Corbin v”): 21,374,021 for, 2,349,550 against, per its Form 8-K filed May 20, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 106 asset managers voting on “Approval of the Company's Non- Employee Director Compensation Policy.” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity3,581,0660 00For
Vanguard2,680,6463,724 110For
BlackRock2,160,3670 00For
Capital Group0755,181 00Against
State Street696,408221 00For
T. Rowe Price373,8460 00For
Manager Directed Portfolios349,2910 00For
First Trust349,2710 00For
Charles Schwab0211,339 00Against
Invesco188,6980 00For
Franklin Custodian Funds0150,000 00Against
TIAA93,1040 00For
WILLIAM BLAIR FUNDS91,5200 00For
Voya67,3170 00For
Equitable63,3340 00For
NEW ECONOMY FUND062,845 00Against
Jackson National58,4320 00For
Dimensional51,8030 00For
Janus Detroit Street Trust48,1800 00For
Columbia Threadneedle44,1210 00For
Nuveen43,7710 00For
John Hancock35,6410 00For
Victory Capital34,8200 00For
Lincoln Financial28,9520 00For
Pacific Life26,8510 00For

Fund voting reports, all 106 managers: 11,509,632 for, 1,250,448 against, 11 abstained, 18,548 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 20 asset managers voting on “Approval of the Company's Non- Employee Director Compensation Policy.” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Frazier Life Sciences Management, L.P.481,3070 00For
Granite Investment Partners, LLC18,2180 00For
ZACKS INVESTMENT MANAGEMENT13,7740 00For
Erste Asset Management GmbH8,7000 00For
Janney Montgomery Scott LLC04,369 00Against
Vident Advisory, LLC1,4810 00For
Sound View Wealth Advisors Group, LLC1,3920 00For
Royal Capital Wealth Management, LLC2780 00For
L2 Asset Management, LLC1390 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC700 00For
Boltwood Capital Management580 00For
AUGUSTINE ASSET MANAGEMENT INC290 00For
Summit Trail Advisors, LLC110 00For
IMA Advisory Services, Inc.100 00For
Keel Point, LLC90 00For
Biltmore Family Office, LLC50 00For
Waverly Advisors, LLC50 00For
Naviter Wealth, LLC20 00For
Performance Wealth Partners, LLC10 00For
White Lighthouse Investment Management Inc.10 00For

Institutional-manager reports, all 20 managers: 525,490 for, 4,369 against.

Ratification of Appointment of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 28,443,155AGAINST: 15,434

Prior year: 100.0% for (May 16, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Krystal Biotech, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm”): 28,443,155 for, 15,434 against — passed, per its Form 8-K filed May 20, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 12,760,222 for, 10,466 against, 4,676 abstained, 18,548 not voted.

FOR
FOR: 12,760,222AGAINST: 10,466ABSTAIN: 4,676NOT VOTED: 18,548
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR” at Krystal Biotech, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity3,581,0660 00For
Vanguard2,684,3820 00For
BlackRock2,160,3670 00For
Capital Group755,1810 00For
State Street696,6290 00For
T. Rowe Price373,8460 00For
Manager Directed Portfolios349,2910 00For
First Trust349,2710 00For
Charles Schwab211,3390 00For
Invesco188,6980 00For
Franklin Custodian Funds150,0000 00For
TIAA93,1040 00For
WILLIAM BLAIR FUNDS91,5200 00For
Voya67,3170 00For
Equitable63,3340 00For
NEW ECONOMY FUND62,8450 00For
Jackson National58,4320 00For
Dimensional51,8030 00For
Janus Detroit Street Trust48,1800 00For
Columbia Threadneedle44,1210 00For
Nuveen43,7710 00For
John Hancock35,6410 00For
Victory Capital34,8200 00For
Lincoln Financial28,9520 00For
Pacific Life26,8510 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Largest Krystal Biotech, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 29,437,000 shares outstanding at the time of that meeting.

Fund voting reports: top Krystal Biotech, Inc. shareholders by shares voted on “TO RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 12.17%
2Vanguard 9.12%
3BlackRock 7.34%
4Capital Group 2.57%
5State Street 2.37%
6T. Rowe Price 1.27%
7Manager Directed Portfolios 1.19%
8First Trust 1.19%
9Charles Schwab 0.72%
10Invesco 0.64%
Institutional-manager reports: top Krystal Biotech, Inc. shareholders by shares voted on “Approval of the compensation of the Company's named executive officers, on a non-binding…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 14.64%
2Avoro Capital Advisors LLC 8.64%
3State Street 3.93%
4BlackRock 2.92%
5Capital Group 2.80%
6Redmile Group, LLC 2.29%
7GEODE CAPITAL MANAGEMENT, LLC 2.10%
8Hood River Capital Management LLC 1.92%
9T. Rowe Price 1.73%
10Frazier Life Sciences Management, L.P. 1.64%

Reported Krystal Biotech, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Krystal Biotech, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)4,373,987 14.86%Form 13F, quarter ended March 31, 2026
FMR LLC4,292,881 14.58%Proxy statement (DEF 14A), table as of March 23, 2026
BlackRock3,940,456 13.39%Form 13F, quarter ended March 31, 2026
Krish S. Krishnan3,388,283 11.51%Schedule 13G, filed May 4, 2026
Vanguard Group2,778,845 9.44%Form 13F, quarter ended March 31, 2026
Avoro Capital Advisors LLC2,565,555 8.72%Proxy statement (DEF 14A), table as of March 23, 2026
Suma M. Krishnan1,664,505 5.65%Proxy statement (DEF 14A), table as of March 23, 2026
State Street1,314,434 4.47%Form 13F, quarter ended March 31, 2026
T. Rowe Price485,074 1.65%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors468,990 1.59%Form 13F, quarter ended March 31, 2026

Percentages above are of 29,437,000 shares outstanding, as reported by Krystal Biotech, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Krystal Biotech, Inc.'s shareholder meeting held May 15, 2026, in the 2025-2026 proxy season, 373 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 2,267 separate fund positions. On the most widely held item on that ballot — Approval of the compensation of the Company's named executive officers, on a non-binding… — Krystal Biotech, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Krystal Biotech, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 20, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Krystal Biotech, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Krystal Biotech, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Krystal Biotech (KRYS) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/krystal-biotech-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.